AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01731197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dry-Blended Beverage
Study NCT01731197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dry-Blended Beverage
Study NCT02391480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-075
Description: ABBV-075 Oral tablets
Study NCT00674752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
Study NCT00674752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
Study NCT02391480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets, film-coated
Study NCT02111603 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Colesevelam
Description: Subjects will receive 1875 mg of Colesevelam orally twice daily for 10 days
Study NCT05567276 — intervention group
Intervention type: BEHAVIORAL
Intervention: Non-Violent Resistance parental training
Description: Non-Violent Resistance parental training
Study NCT04187339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM395
Description: NGM395 Dose 1
Study NCT04187339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM395
Description: NGM395 Dose 2
Study NCT04187339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM395
Description: NGM395 Dose 3
Study NCT04187339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM395
Description: NGM395 Dose 4
Study NCT04187339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM395
Description: NGM395 Dose 5
Study NCT04187339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM395
Description: NGM395 Dose 6
Study NCT04187339 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02556463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9197
Description: Subjects will receive MEDI9197 (every 4 weeks) as monotherapy (or MEDI9197 every 8 weeks + durvalumab every 4 weeks)(PA6)
Study NCT02369211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen (Ofirmev)
Description: The patient was administered IV Ofirmev during anesthesia and then 3 more IV doses (1g each) every 6 hours up to 24 hrs.
Study NCT02369211 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient was administered IV Placebo during anesthesia and then 3 more doses of IV Placebo every 6 hours up to 24 hrs.
Study NCT02556463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Subjects will receive durvalumab every 4 weeks
Study NCT00674752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo oral capsule 30 minutes prior to bedtime
Study NCT00571298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extrapleural pneumonectomy (EPP)
Description: Resection of the lung, the lining of the lung (pleura), the covering of the heart (pericardium), and the muscle that separates the chest and abdomen (diaphragm)
Study NCT00571298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given after the tumor is removed as a bath (perfusion) for one-hour
Study NCT00571298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Given after the tumor is removed as a bath (perfusion) for one-hour
Study NCT00571298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine
Description: Given intravenously before perfusion chemotherapy and then 2 hours after the first dose
Study NCT00571298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium thiosulfate
Description: Given intravenously immediately at the end of perfusion chemotherapy
Study NCT04534179 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity program.
Description: Active Comparator: Physical activity The exercise protocol would last 5 weeks, performing 3 exercise sessions per week, with an effective work time of 20 minutes per session. The exercises would be directly focused on activating the core stabilizing muscles.
Study NCT02672059 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: No intervention
Study NCT01092780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7288
Description: one or two 10 mg capsules, orally, single dose
Study NCT01092780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-7288
Description: one or two capsules, orally, single dose
Study NCT01895569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be added to therapy for the first threre months.
Study NCT01895569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: In patients not well controlled (glycated hemoglobin >6.5%) after three months of metformin, pioglitazone will be added.
Study NCT01092780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: two 100 mg tablets, orally, single dose
Study NCT00571298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pleurectomy/Decortication
Description: Resection of the lining of the lung (pleura), while the lung remains intact.
Study NCT00040911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electroacupuncture therapy
Study NCT01092780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to modafinil
Description: two 100 mg tablets, orally, single dose
Study NCT04353089 — intervention group
Intervention type: OTHER
Intervention: Basic life support courses
Description: 4 hours certified basic life support courses
Study NCT02118870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment 90 days DAPT
Description: Short term DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 90 days, after which patients will continue.
Study NCT02118870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment 360 days DAPT
Description: Long term (360 days) DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge
Study NCT03617315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylauronic Acid
Description: Schirmer Test, BUT test and OSDI test. Previous and After treatment
Study NCT00035100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epothilone b
Study NCT04989296 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peripheral blood samples were obtained following the standard procedures.
Description: Taking 4 ml of peripheral blood from patients on an empty stomach.
Study NCT01760382 — intervention group
Intervention type: DEVICE
Intervention: Primary PCI
Description: mechanical reopening of the STEMI-related coronary artery by PTCA, with or without coronary stent implantation
Study NCT00040911 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham intervention
Description: Undergo electroacupuncture therapy to sham points
Study NCT00040911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00040911 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT03109535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit + Maptrek
Description: Users receive a Fitbit Zip to wear daily. Users aslo receive the mHealth MapTrek game that places users in weekly walking races and sends automated text messages to users on a daily basis for the purpose of increasing daily physical activity.
Study NCT03109535 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit only
Description: Users receive a Fitbit Zip to wear daily.
Study NCT02545049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)
Description: 10 mg or 20 mg Finerenone tablet to be given orally, once daily.
Study NCT02545049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to be taken orally, once daily.
Study NCT00286156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamune
Description: Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml Group 3- Standard Care
Study NCT04830657 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Distant reiki
Description: In order to determine the sample size of the study, it is planned to study with a total of 62 patients, including at least 31 patients in each group, in the power analysis based on the statistics of the statistician and previous studies. The remote reiki group will be given remote reiki 3 times a week for 4 weeks by the researcher who has a reiki application certificate. Remote reiki sessions will be performed by the reiki practitioner the night before the hemodialysis day of the patient, and the session duration will take approximately 36-40 minutes. After the individuals receive 12 sessions of remote reiki (1 month later), the questionnaire will be filled in for the second measurement. In order to determine whether reiki has an effect in the long term, 4 weeks (1 month) after the second measurement, the questionnaire for the third measurement will be completed and the research will be completed.
Study NCT04830657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distant reiki
Description: In order to determine the sample size of the study, it is planned to study with a total of 62 patients, including at least 31 patients in each group, in the power analysis based on the statistics of the statistician and previous studies. The remote reiki group will be given remote reiki 3 times a week for 4 weeks by the researcher who has a reiki application certificate. Remote reiki sessions will be performed by the reiki practitioner the night before the hemodialysis day of the patient, and the session duration will take approximately 36-40 minutes. After the individuals receive 12 sessions of remote reiki (1 month later), the questionnaire will be filled in for the second measurement. In order to determine whether reiki has an effect in the long term, 4 weeks (1 month) after the second measurement, the questionnaire for the third measurement will be completed and the research will be completed.
Study NCT00781183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: 6-weeks of in-patient pulmonary rehabilitation or 12-weeks of out-patient pulmonary rehabilitation
Study NCT00792857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTAP201 Injection
Description: Comparison of different dose strengths of CTAP201 after single dose.
Study NCT00792857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxercalciferol
Description: Comparison of different dose strengths of doxercalciferol after single dose.
Study NCT00653198 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03260062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Child Early Approaches to Raising Language Skills
Description: The PEARLS intervention will teach parents evidence-based language strategies and sensitive parenting (e.g., warmth, respect for autonomy, linguistic stimulation) to promote language development in young deaf children with cochlear implants (CI).
Study NCT03260062 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Speech therapy
Description: Families will participate in auditory-verbal therapy, which is the standard speech therapy with children with hearing loss.
Study NCT01320553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1102 I
Description: SPARC1102 I will be administered in both eyes
Study NCT01320553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1102 II
Description: SPARC1102 II will be administered in both eyes
Study NCT01320553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1102 III
Description: SPARC1102 III will be administered in both eyes
Study NCT01320553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle will be administered in both eyes
Study NCT00614445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg
Description: up to 4 tablets daily, titrated according to the protocol
Study NCT00614445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 to 4 tablets daily titrated according to the protocol
Study NCT02592720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cocktail
Description: Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
Study NCT02592720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFR
Description: Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
Study NCT02592720 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: QCA guided group
Description: Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
Study NCT00868088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PDT prior to Mohs surgery
Description: Day 1: Screening and consent for this study. If eligible, a scouting biopsy will be obtained at 1 cm from the clinical border of the SCC for confirmation of AC.~7-14 Days after consultation: PDT to all subjects in the study. If during treatment a subject requests to discontinue due to pain the treatment will be terminated.~3-5 weeks after consultation: return for assessment. At this visit, the assigned treatment may be repeated if the treatment site is adequately healed. Re-treatment will only occur if there is persistent actinic damage.~6-8 weeks after consultation: Mohs surgery will be performed as per routine. Following tumor removal a scouting biopsy will be taken at a site 1 cm from the wound site created by SCC removal. The current waiting time for non-urgent surgery is 8 weeks. Standard care is not being altered for subjects in the study, other then their receiving the PDT intervention.~Photographs may be taken at each subject visit.
Study NCT00868088 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PDT prior to Mohs surgery
Description: Day 1: Screening and consent for this study. If eligible, a scouting biopsy will be obtained at 1 cm from the clinical border of the SCC for confirmation of AC.~7-14 Days after consultation: PDT to all subjects in the study. If during treatment a subject requests to discontinue due to pain the treatment will be terminated.~3-5 weeks after consultation: return for assessment. At this visit, the assigned treatment may be repeated if the treatment site is adequately healed. Re-treatment will only occur if there is persistent actinic damage.~6-8 weeks after consultation: Mohs surgery will be performed as per routine. Following tumor removal a scouting biopsy will be taken at a site 1 cm from the wound site created by SCC removal. The current waiting time for non-urgent surgery is 8 weeks. Standard care is not being altered for subjects in the study, other then their receiving the PDT intervention.~Photographs may be taken at each subject visit.
Study NCT03385915 — intervention group
Intervention type: PROCEDURE
Intervention: Aortic valve replacement
Description: Transcatheter or surgical aortic valve replacement for severe aortic valve stenosis
Study NCT04579536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light curable resin modified glass ionomer varnish
Description: Light curing resin-modified glass ionomer varnish (ClinproTM XT Vanish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used to seal 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
Study NCT02631369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heidelberg Spectralis OCT device
Study NCT02172560 — intervention group
Intervention type: DRUG
Intervention: Tiotropium
Study NCT04738656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Diet plan
Description: Mediterranean style is a non-restricted diet plan compared with the open protein diet plan
Study NCT05489913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac rehabilitation support program
Description: First of all, a preliminary interview was made with the patients in the experimental group, and their information needs were evaluated individually. Which trainings he should receive and his priorities were determined with the patient. After the training requirements were determined, the general introduction of the website was made and they were allowed to register. Experimental group patients received both training on the website and counseling over the phone for 12 weeks after they started working. A total of 3 phone calls were made with the patients in the first week, 4th and 8th weeks. The interviews lasted an average of 20 minutes. In each phone call, patients were informed and reminded. When patients needed, an average of 2-3 more phone calls were made and information was provided on the subjects they needed.
Study NCT01437319 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon A
Description: To be used during run-in phase only.
Study NCT01437319 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: To be assigned at randomization at phase 2 only.
Study NCT01437319 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: To be assigned at randomization during phase 2 only.
Study NCT01437319 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: Assigned to Neophytes during Phase I for a 2-week period
Study NCT01025128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25 OH vitamin D
Description: oral supplementation of 25 OH vitamin D at dose of 2000 units/d for 3 months then 1000 units/d for 3 months
Study NCT01895569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: In patients not well controlled (glycated hemoglobin >6.5%) after three months of metformin and pioglitazone, sitagliptin will be added.
Study NCT04011761 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: expert arbitration over discordant diagnoses made by AI diagnostic system and human doctors, respectively
Description: Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the experimental arm will be referred to an expert arbitrator for differential and decisive diagnosis and will receive treatment prescribed by the expert arbitrator.
Study NCT00288288 — intervention group
Intervention type: PROCEDURE
Intervention: Epicardial left ventricular lead placement
Description: Epicardial left ventricular lead placement
Study NCT00288288 — intervention group
Intervention type: PROCEDURE
Intervention: Transvenous left ventricular lead implant
Description: Transvenous left ventricular lead implant
Study NCT04439500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real World Strategy Training
Description: The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
Study NCT00280098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel 75mg/m2/q3wx10 cycles with Prednisone 10mg/d/bid
Study NCT03198234 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-allo10
Description: The T-allo10 drug product consists of donor derived, host (patient) alloantigen hyporesponsive (anergic) CD4+ (cluster of differentiation 4) cells containing Type 1 regulatory T (Tr1) cells induced in vitro in the presence of IL-10 (interleukin-10), which are also defined as IL-10 anergized T cells. T-allo10 cell infusion is being developed to prevent acute Graft-versus-Host Disease (GvHD) and induce graft tolerance in patients with hematologic malignancies receiving mismatched related and unrelated unmanipulated hematopoietic stem cell transplant (HSCT).
Study NCT03637114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude (FiO2: 15.1%)
Description: Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask.
Study NCT04439500 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Education
Description: The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sodoku puzzles. Homework will consist of reading assignments related to the session topics.